ArticleClinical cancer research : an official journal of the American Association for Cancer Research2025
Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Liquid biopsy: current applications and future directions.Molecular biomedicine · 2026Review
- Emerging liquid biopsy markers in thyroid cancer: from isolation technologies to clinical translation.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeNext-generation sequencing assays for ctDNA analysis are routinely used in the care of patients with advanced non-small cell lung cancer. However, variable assay sensitivities in detection of fusions have been reported. Here, we report on the performance of detecting RET rearrangements in plasma across three commercial next-generation sequencing laboratories. EXPERIMENTAL
designBanked plasma from the phase 3 LIBRETTO-431 trial was studied. For each patient (n = 60) with a known RET fusion by local tumor tissue genotyping, pretreatment plasma was divided into two 3-mL aliquots and tested on two of three: Guardant Health's Guardant360, Foundation Medicine's FoundationOneLiquid CDx, and Resolution Bioscience's ctDx-First. A round-robin comparison was performed across vendors using three pairwise comparisons of 20 patients each. On an exploratory basis, agreement of fusion breakpoint calling between plasma and tissue and determinants of false negatives in plasma were assessed.
resultsOf 40 samples received by each laboratory, 100% (40/40), 92.5% (37/40), and 90% (36/40) were successfully sequenced by Guardant360, FoundationOne Liquid CDx, and ctDx-First, with a RET fusion or rearrangement detected in 60% (24/40), 63.9% (23/36), and 67.6% (25/37) of cases, respectively. Discordant results included rare and common RET translocations but were usually below allelic frequency of 0.5%. Of samples with a RET fusion detected in plasma and a reported fusion partner by tumor assay, the same fusion partner was identified in tissue and liquid 81% to 89% of the time.
conclusionsOur results support the utility of ctDNA assays concurrently with tissue testing for detection of translocations, with opportunities to further optimize performance. See related commentary by Davies, p. 2264.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.